In this study, we conducted a targeted metabolomic analysis of an AOM‐DSS‐induced CAC model across three stages – UC, Dys, and CAC, which enabled us to systematically map both temporal (colitis‐to‐dysplasia‐to‐carcinoma) and spatial (normal‐to‐NAT‐to‐tumor) metabolic shifts during the inflammation‐to‐cancer progression. The gene discussed is BRD2; the disease is dysplasia.